Skip to content

Garlic fovourable modifies hsCRP and PAI-1 level in overweight and obese hypertensive patients- a double-blind, placebo controlled, randomized trial.

Garlic fovourable modifies hsCRP and PAI-1 level in overweight and obese hypertensive patients- a double-blind, placebo controlled, randomized trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00010533
Enrollment
92
Registered
2016-05-20
Start date
2015-01-12
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of garlic extract on selected biochemical parameters in obese patients with hypertension. E66

Interventions

Group 1: Study group - 400mg of garlic extract (capsules) /day, duration of treatment - 3 months Group 2: Placebo group - 400mg/d placebo (pure midrocrystalline cellulose) for 3 months

Sponsors

Department of Education and Obesity Treatment and Metabolic Disorders
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 60 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were a body mass index (BMI) equal to or greater than 30 kg/m2, age 25 to 60 years, stable body weight (< 3 kg self-reported change during the previous three months), and no drug- treated hypertension (meaning systolic blood pressure (SBP) less than 160 mmHg and diastolic blood pressure (DBP) less than 100 mmHg) with stable treatment for at least 6 months (diet, physical activity, life style). The treatment scheme was comparable for both the placebo and the garlic group.

Exclusion criteria

Exclusion criteria: The exclusion criteria were secondary obesity or secondary hypertension; diabetes; a history of coronary artery disease, stroke, congestive heart failure, or malignancy; a history of use of any dietary supplements within the three months prior to the study; a current need for modification of antihypertensive therapy; abnormal liver or kidney function; any clinically significant process; a history of infection in the month prior to the study; nicotine or alcohol abuse; or other condition that, in the opinion of the investigators, would make participation not in the best interest of the patient or could prevent, limit, or confound the protocol-specified efficacy assessments.

Design outcomes

Primary

MeasureTime frame
The values of inflammation markers and PAI-1 level before and after 3 months of suplementation of Garlic extract

Secondary

MeasureTime frame
The values of blood pressure before and after 3 months of suplementation of Garlic extract. The values of stiffnes index before and after 3 months of suplementation of Garlic extract The levels of lipid parameters before and after 3 months of suplementation of Garlic extract

Countries

Poland

Contacts

Public ContactPawel Bogdanski

Department of Education and Obesity Treatment and Metabolic Disorders

pawelbogdanski@wp.pl+48 61 8549377

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026